Palatin Technologies' Phase 2 study reveals that patients on the obesity drug bremelanotide in combination with tirzepatide achieved a 4.4 percent weight reduction, highlighting the synergistic effect of the two mechanisms. The company is also addressing the challenge of weight regain and advancing the development of new drug applications. With the obesity treatment market projected to reach $100 billion by 2030, Palatin is well-positioned in this rapidly expanding market.